Absorption, Distribution, Metabolism, and Excretion of Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), in Healthy Male Subjects

被引：0
|
作者：
Bourdet, D. [1 ]
Yeola, S. [1 ]
Colson, P. [1 ]
Pendyala, S. [1 ]
Barnes, C. N. [1 ]
Borin, M. [1 ]
机构：
[1] Theravance Biopharma US Inc, San Francisco, CA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3033
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study
    Borin, M.
    Barnes, C.
    Darpo, B.
    Pendyala, S.
    Bourdet, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [2] Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects
    Weber, C
    Gasser, R
    Hopfgartner, G
    DRUG METABOLISM AND DISPOSITION, 1999, 27 (07) : 810 - 815
  • [3] Absorption, metabolism, and excretion of rolapitant, a highly selective and long-acting NK-1 antagonist, in healthy volunteers
    Zhang, Zhi-Yi
    Wang, Xiaodong
    Powers, Dan
    Lu, Sharon
    Wang, Jing
    Christensen, Jennifer
    Kansra, Vikram
    DRUG METABOLISM REVIEWS, 2016, 48 : 50 - 51
  • [4] Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study
    Bonin, Marie T.
    Barnes, Chris N.
    Darpo, Borje
    Pendyala, Srikanth
    Xue, Hongqi
    Bourdet, David L.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (01): : 130 - 139
  • [5] Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite
    Bourdet, David L.
    Yeola, Suresh
    Hegde, Sharath S.
    Colson, Pierre-Jean
    Barnes, Chris N.
    Borin, Marie T.
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (12) : 1312 - 1320
  • [6] A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
    Sion K.Y.J.
    Huisman E.L.
    Punekar Y.S.
    Naya I.
    Ismaila A.S.
    Pulmonary Therapy, 2017, 3 (2) : 297 - 316
  • [7] Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD
    Edwards, Sarah
    Orme, Mark
    Harvey-Dunstan, Theresa
    Tal-Singer, Ruth
    Polkey, Michael
    Steiner, Michael
    Morgan, Mike
    Singh, Sally
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [8] Repeateddose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA) in subjects with COPD
    Bourdet, David
    Barnes, Chris
    Yates, Wayne
    Moran, Ed
    Nicholls, Andrew
    Haumann, Brett
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [9] EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE
    Donohue, James
    Kerwin, Edward
    Barnes, Chris
    Moran, Edmund
    Haumann, Brett
    Pendyala, Srikanth
    Crater, Glenn
    CHEST, 2018, 154 (04) : 736A - 737A
  • [10] Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
    Teng, Renli
    Oliver, Stuart
    Hayes, Martin A.
    Butler, Kathleen
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (09) : 1514 - 1521
12345